Fosamax and Osteonecrosis of the Jaw: Understanding Long-Term Prognosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of bone health and pharmaceutical interventions have been standard, with emphasis on maintaining skeletal integrity and managing conditions like osteoporosis. This general framework provided accessible knowledge about common therapies, including bisphosphonates such as Fosamax, which were widely prescribed to reduce fracture risk. However, as clinical experience accumulated, the focus shifted from general efficacy to specific, rare adverse events. Among these, osteonecrosis of the jaw (ONJ) emerged as a significant concern, particularly in patients with prolonged Fosamax exposure. This transition from broad health education to a targeted risk assessment marks a critical evolution in medical discourse. The prognosis for ONJ following Fosamax use now demands careful consideration, as long-term outcomes vary based on individual patient factors and exposure duration.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The clinical presentation of ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis typically involves clinical examination revealing exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, or infection. The condition is considered a bone-related complication that can be better understood through multiscale characterization of jawbone tissue, which provides comprehensive information on jawbone-specific responses to bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms and Risk Factors for ONJ in Fosamax Users

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption. This suppression of bone turnover can impair the jawbone's ability to remodel and repair microdamage, particularly after invasive dental procedures. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for fracture prevention, noting that the optimal duration of use has not been determined and that for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Prognosis and Long-Term Outcomes After Fosamax Exposure

Prognosis-related considerations for affected patients are informed by available data. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Long-term outcome data from a large cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink indicate that the absolute risk of ONJ remains low, approximately 0.05% after 5 years of treatment, and diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). The same study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, suggesting a cumulative dose-response relationship (https://pubmed.ncbi.nlm.nih.gov/39400702/). The timeline between exposure and documented harm is variable. Symptoms can appear as early as one day after starting the drug, but the risk increases with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The cohort study data show that risk escalates with cumulative treatment duration, with a threefold increase after 2-3 years and an eightfold increase after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). Importantly, the risk diminishes after discontinuation, indicating that cessation of bisphosphonate therapy may improve prognosis (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, management typically involves conservative measures such as oral antimicrobial rinses, antibiotics, and avoidance of invasive dental procedures in the affected area. In severe cases, surgical debridement may be necessary, though outcomes can be complicated by impaired bone healing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

The prognosis is generally favorable with drug discontinuation. Most patients experience relief of symptoms after stopping Fosamax, though a subset may have recurrence if rechallenged. Long-term data show that the absolute risk of ONJ is low (about 0.05% after 5 years) and diminishes after discontinuation. However, risk increases with longer exposure duration, with an eightfold increase after 10 years compared to past use.

How long after starting Fosamax can osteonecrosis of the jaw occur?

Symptoms can appear as early as one day after starting the drug, but the risk increases with longer duration of exposure. The time to onset varies from one day to several months. Cumulative exposure is a key factor, with risk escalating after 2-3 years and further after 10 years.

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use also increases risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.